Drug Discovery Group, Queensland Institute of Medical Research, Post Office Royal Brisbane and Women's Hospital, Brisbane, QLD 4029, Australia.
Expert Rev Anticancer Ther. 2011 May;11(5):725-37. doi: 10.1586/era.11.25.
Malignant melanoma, a tumor arising from the transformation of melanocytes, has been increasing in incidence worldwide for the past three decades. Melanoma that has metastasized is usually highly resistant to standard chemotherapy. The standard of care for patients with metastatic melanoma has not changed significantly in the past 20 years, and new strategies for treatment of metastatic melanoma are urgently needed. Significant insights have recently been gained into the molecular events underpinning the development of melanoma. A number of novel compounds designed to target these molecular events, as well as monoclonal antibodies to key immune regulatory functions, have been developed and used in clinical trials. The results of these trials hold great promise for the treatment of subsets of patients with metastatic melanoma.
恶性黑素瘤是一种起源于黑素细胞转化的肿瘤，在过去三十年中，其发病率在全球范围内呈上升趋势。转移性黑素瘤通常对标准化疗高度耐药。过去 20 年来，转移性黑素瘤患者的治疗标准没有显著改变，迫切需要新的治疗转移性黑素瘤的策略。最近，人们对导致黑素瘤发展的分子事件有了重要的了解。已经开发出许多旨在针对这些分子事件的新型化合物，以及针对关键免疫调节功能的单克隆抗体，并已在临床试验中使用。这些试验的结果为治疗转移性黑素瘤的某些亚组患者带来了巨大的希望。
